Syneos Health Inc. (NASDAQ:SYNH) finished Wednesday with an addition of $0.05 to close at $42.61, an upside of 0.12 percent. An average of 1,133,840 shares of common stock have been traded in the last five days. There was a gain of $0.26 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,224,405 shares traded, while the 50-day average volume stands at 1,636,042.
SYNH stock has increased by 0.59% in the last month. The company shares reached their 1-month lowest point of $42.21 on 07/11/23. With the stock rallying to its 52-week high on 02/27/23, shares of the company touched a low of $22.89 and a high of $71.68 in 52 weeks. It has reached a new high 6 times so far this year and achieved 16.17% or $5.93 in price. In spite of this, the price is down -40.55% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Syneos Health Inc. (SYNH) has a trailing price-to-earnings (P/E) ratio of 29.65. The stock’s beta is 1.58. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.82, the price-to-book (PB) ratio at 1.27, and the price-to-cash flow ratio at 15.28.
Financial Health
The quick ratio of Syneos Health Inc. for the three months ended March 30 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.77 and a total debt to equity ratio of 0.77 for the quarter ending March 30. Syneos Health Inc.’s EBITDA margin for the year ending March 30 is 13.10%, while its operating margin for the same period stands at 5.30%. Its gross profit as reported stood at $1.25 billion compared to revenue of $5.39 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Syneos Health Inc.’s return on assets was 1.80%.
Earnings Surprise
For the three-month period that ended March 30, Syneos Health Inc. had $2.61 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$72.15 million in the quarter, while revenues of $55.53 million were grew 164.01%. The analyst consensus anticipated Syneos Health Inc.’s latest quarter earnings to come in at $0.66 per share, but it turned out to be $0.75, a 13.60% surprise. For the quarter, EBITDA amounted to $22.05 million. Shareholders own equity worth $103.65 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Syneos Health Inc. (SYNH) price momentum. RSI 9-day as of the close on 09 August was 71.21%, suggesting the stock is Overbought, with historical volatility in this time frame at 2.03%.
As of today, SYNH’s price is $42.52 +0.61% or $0.26 from its 5-day moving average. SYNH is currently trading +0.83% higher than its 20-day SMA and +24.08% higher than its 100-day SMA. However, the stock’s current price level is +2.43% above the SMA50 and -8.27% below the SMA200.
The stochastic %K and %D were 77.10% and 77.05%, respectively, and the average true range (ATR) was 0.14. With the 14-day stochastic at 70.45% and the average true range at 0.16, the RSI (14) stands at 67.96%. The stock has reached 0.08 on the 9-day MACD Oscillator while the 14-day reading was at 0.10.
Analyst Ratings
JP Morgan downgraded Syneos Health Inc. (NASDAQ: SYNH) to a an Underweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Syneos Health Inc. (SYNH) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SYNH, while 11 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
